...
首页> 外文期刊>ACS Omega >Molecular Cobalt(II) Complexes for Tau Polymerization in Alzheimer’s Disease
【24h】

Molecular Cobalt(II) Complexes for Tau Polymerization in Alzheimer’s Disease

机译:阿尔茨海默氏病中Tau聚合的分子钴(II)配合物

获取原文

摘要

Tau is an axonal protein known to form abnormal aggregates and is the biomarker of Alzheimer’s disease. Metal-based therapeutics for inhibition of Tau aggregation is limited and rarely reported in contemporary science. Here, we report the first example of rationally designed molecular cobalt(II)-complexes for effective inhibition of Tau and disaggregation of preformed Tau fibrils. The mechanistic studies reveal that prevention of Tau aggregation by cobalt-based metal complexes (CBMCs) is concentration-dependent and Tau seldom exhibits conformational changes. Interestingly, CBMCs play dual role in causing disassembly of preformed aggregates as well as inhibition of complete Tau aggregation. Furthermore, CBMCs were nontoxic and maintained the tubulin network intact. CBMCs also prevented okadaic acid-induced toxicity in SH-SY5Y cells thus, preventing hyperphosphorylation of Tau. We believe that this unprecedented finding by the newly developed molecular complexes has a potential toward metal-based therapeutics for Alzheimer’s disease.
机译:Tau是一种已知会形成异常聚集体的轴突蛋白,是阿尔茨海默氏病的生物标记。抑制Tau聚集的基于金属的治疗方法有限,在当代科学中很少报道。在这里,我们报告合理设计的分子钴(II)配合物的第一个例子,可以有效抑制Tau和使预制的Tau原纤维分解。机理研究表明,钴基金属配合物(CBMC)阻止Tau聚集是浓度依赖性的,Tau很少显示构象变化。有趣的是,CBMC在导致预制聚集体的分解以及抑制Tau聚集体中起双重作用。此外,CBMC无毒,并保持微管蛋白网络完整。 CBMCs还防止了冈田酸对SH-SY5Y细胞的毒性,从而防止了Tau的过度磷酸化。我们相信,新开发的分子复合物的这一前所未有的发现对于治疗老年痴呆症的金属疗法具有潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号